Envestnet Portfolio Solutions Inc. Invests $216,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Envestnet Portfolio Solutions Inc. acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,177 shares of the biopharmaceutical company’s stock, valued at approximately $216,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TGTX. State Street Corp lifted its stake in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of TG Therapeutics in the fourth quarter worth $14,508,000. Braun Stacey Associates Inc. acquired a new stake in TG Therapeutics during the fourth quarter valued at approximately $13,328,000. Finally, Castellan Group bought a new position in TG Therapeutics during the fourth quarter worth $8,539,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Price Performance

TGTX opened at $39.86 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $6.26 billion, a PE ratio of -398.56 and a beta of 2.30. The company has a fifty day moving average price of $34.37 and a two-hundred day moving average price of $30.29. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.